"In ACCELLENA, we have found a reliable partner in the development of new pharmacologically active substances discovered in our laboratories. In almost three years of joint development, we have almost completed the preclinical development stage and are close to the first in human study initiation."

Prof. Raul Gainetdinov

Professor, Head of Laboratory of Neuroscience and Molecular Pharmacology at St. Petersburg State University
"Over the years of cooperation with ACCELLENA, we have participated in dozens of joint clinical research projects. Prompt resolution of issues, professionalism and involvement are the main features of our colleagues from ACCELLENA."
Dr. Viktoria Dedkova
Deputy head of Scientific research center “Eco-Safety”
"Our ethics committee has been providing support for clinical trials conducted by ACCELLENA for more than five years. Consistent quality of the documents provided, effective communication in solving emerging issues - all this contributes to the quality and ethics of the research conducted by the company."
Mrs. Marina Zakharova
Executive secretary at Independent Ethics Committee “BioEthics”
Early phases expertise
To date, the company has conducted 15 phase I trials and 6 phase I/II trials of small molecules, biologics and medical devices. Alltogether, more than 1800 subjects were included in these early studies.

Back in 2019, a Middle East Respiratory Syndrome (MERS) vaccine study was launched, laying the foundation for the success of two first-in-human clinical trials in 2020 of one of the world’s first Sputnik V vaccines against novel coronavirus infection (SARS-CoV-2) in very difficult conditions of the anti-epidemic measures.

Since 2015, the company has participated in 28 clinical bioequivalence (BE) studies, including studies with replicative design, pharmacodynamic endpoints, fasting or fed conditions. In total, more than 1,000 participants took part in these studies.

Early phases cases
A representative selection of relevant cases
Late phases expertise
Accellena's first clinical trial in 2015 was a proof-of-concept trial of an antitumor drug conducted in the USA, Europe and the CIS. By 2018, the company conducted more than 15 clinical trials, and by mid-2022, we took part in more than 70 clinical trial projects.

More than 25 of these were late phase clinical trials at various stages, including 15 completed by today.

The company has acquired the greatest experience in late phase research in the following areas: research on vaccines, infectious diseases, oncology, neurology, gastroenterology and surgery.

The company's experience is not limited to clinical trials. Since 2015, Accellena has been involved in major case-control epidemiological studies in the field of infectious diseases. We has successfully conducted a study of medical nutrition, cellular biomedical products (CAR-T therapy), and are actively involved in the study of the safety and efficacy of medical devices, both diagnostic and used for treatment, including life-threatening conditions in CPR units.
Late phases cases
A representative selection of relevant cases
RWD/RWE expertise
To date, the company has conducted three research projects using real clinical practice data.

The first of these was the study of the use of hormone therapy in the treatment of breast cancer. Despite the relatively small number of participants, much attention was paid to the duration of follow-up of health status, as well as the qualitative assessment of response to treatment according to RECIST.

The other two projects were large case-control epidemiological studies to study the preventive efficacy of an antiviral agent and an influenza vaccine in large (several thousand people) production teams.

Within the framework of these projects, issues related to the comprehensive collection of data on incidence in the entire study population were successfully resolved.
RWD/RWE cases
A representative selection of relevant cases
ACCELLENA headquarters:

Tel.: +7 (812) 337 58 66
Fax: +7 (812) 337 58 06

88, lit.A., Sredniy pr. V.O.,
St. Petersburg, Russia,

Kesklinna linnaosa, Vesivärava
tn 50-201, Estonia, Tallinn,
By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively.